April 27, 2018
8:30-10:20 Tau functions and therapeutics
8:30- 8:50 Zilka N (Axon Neuroscience) Let’s target disease tau and keep normal tau alive
8:50- 9:10 Courade JP (UCB Pharma) Tau antibodies are not born equal: epitope determine efficacy.
9:10- 9:30 Gozes I (Israel) Overexpression of recombinant ADNP significantly enhances microtubule dynamics: implication for the ADNP syndrome and neurodegenerative tauopathies
9:30- 9:45 Papanikolopoulou K (Greece) Altered proteostasis and neuroplasticity upon tau loss in Drosophila
9:45-10:00 Ching-Pang Chang (Taiwan) Beneficial effects of an adenosine augmentation compound (J4) in a mouse model of tauopathy
10:00-10:15 Melnyk P (France) New piperazine multi-action drugs prevent neurofibrillary degeneration and amyloid deposition, and improve memory in AD animal models
10:15-10:45 Coffee break
10:45-12:00 Structure & functions
10:45-11:05 Goedert M (UK) The cores of tau filaments
11:05-11:25 Serpell L (UK) Getting to the core of PHF
11:25-11:45 Margittai M (USA) To grow or not to grow: Tau fibril structure at the crossroads of seeding
11:45-12:05 Brandt R (Germany) Tau in the axon: Kiss-and-hop with microtubules and on the leash of annexins
12:05-12:25 Uytterhoeven V (Belgium) Reduction of Tau-synaptic vesicle associations alleviates presynaptic dysfunction
12:25-12:45 de Silva R (UK) MAPT-AS1, an antisense long non-coding RNA gene is a translational repressor of tau gene expression
12:45-14:00 Lunch & Poster session
14:00-14:45 Tau functions and dysfunctions
14:00-14:15 Devred F (France) Temperature-dependent reversible oligomerization of tau
14:15-14:30 Giustiniani J (France) FKBP52 decrease in neurons modulates autophagy and tau secretion
14:30-14:45 Smet-Nocca C (France) Identification of the phosphorylation pattern that drives tau aggregation
14:45-15:15 Flash-talks of selected posters
P3,P28,P40,P48,P52,P58
15:15-15:30 Awards
15:30-16:30 Informal discussion & poster session
16:30 Closing of the meeting
April 26, 2018
9:00 Welcome coffee - Poster setup
9:30 Introduction: Luc Buée
9:40-12:00 experimental models & atypical tau functions
9:40-10:00 Lefebvre B (France) DDX proteins: tau nuclear partners
10:00-10:20 Hanger D (UK) Animal and cell models of Tauopathy
10:20-10:40 Mudher A (UK) Wlds confers bystander protection against tau-mediated degeneration in a Drosophila model of tauopathy
10:40-11:00 Novak M/Smolek T (Slovakia) Humanized rat tau model for AD
11:00-11:20 Planel E (Canada) Regulation of tau by temperature
11:20-11:40 Mandelkow EM (Germany) Trans-neuronal transmission of Tau protein by exosomes
11:40-12:00 Takashima A (Japan) AMPA/NMDA stimulation causes somato dendritic localization of pTau protein: local translation of tau in dendrite
12:00-13:30 Lunch and Poster session
13:30-16:00 Tau pathology
13:30-13:45 Milutinovic M (Quanterix) Simoa: Ultrasensitive immuno-assays for detection of tau and CNS biomarkers in serum & plasma
13:45-14:00 Verelst J (Belgium) A new panel of novel Tau monoclonal antibodies, rendering new insights in Tau structure and diagnosis
14:00-14:20 Ando K, Brion JP (Belgium) Alzheimer risk PICALM
14:20-14:40 Attems J (UK) Impact of cortical tau pathology on white matter integrity
14:40-15:00 Kovacks G (Austria) Astroglia and Tau: new perspectives
15:00-15:15 Hanseeuw B (Belgium) From amyloid and tau to cognitive decline: Serial PET measures ...
15:15-15:30 Perrotin A (Piramal) 18F-PI-2620, clinical evaluation of a next generation tau PET agent in subjects with AD and PSP
15:30-15:45 Sanchez-Juan P (Spain) MAPT genetic variants and neurodegenerative diseases in Spanish population.
15:45-16:00 Caffrey TM (UK) MAPT genetic variations and neuronal maturity regulate alternatively-spliced exon expression
16:00-16:30 Coffee break and poster session
16:30-18:35 Tau dysfunctions and consequences
16:30-16:50 Medina M (Spain) Role of the N-terminal domain in tau secretion
16:50-17:10 Wegmann S (USA) Tau protein liquid-liquid phase separation: a novel way to initiate tau aggregation in the brain
17:10-17:30 Sotiropoulos I (Portugal) Endolysosomal sorting and degra-dation of tau and its role in glucocorticoid-driven hippocampal malfunction
17:30-17:50 Scheper W (NL) The UPR and tau pathology
17:50-18:05 Evans L (UK) Internalization and vesicular trafficking of tau in human forebrain neurons
18:05-18:20 Lastres-Becker I (Spain) Impaired signaling of transcription factors NF-kB and NRF2 in CX3CR1-deficient microglia leads to altered neuroinflammation and phagocytosis: implications in Tauopathies
18:20-18:35 Di Primio C (Italy) Behing the nuclear envelop: tau involved in gene regulation
"Cras elementum ultrices diam."
A service on your city
Alzheimer & Tauopathies - Luc Buée
Copyright 2018